Bausch + Lomb Corporation (BLCO) Stock Price & How to Invest

Bausch + Lomb is one of the oldest and best-known names in eye health, operating across three segments: Vision Care (roughly 57% of sales, spanning contact lenses like Biotrue and lens-care solutions plus consumer eye drops such as LUMIFY and PreserVision supplements), Pharmaceuticals (around 25%, led by the dry-eye drug MIEBO and international brands), and Surgical (about 18%, including intraocular lenses, phacoemulsification systems and cataract and retina instruments). Full-year 2025 revenue reached roughly $5.1 billion, trailing twelve-month revenue is now about $5.3 billion, and the company sells into the structurally growing markets of an aging population, rising myopia and expanding cataract volumes.

The investment picture is a mix of genuine operating improvement and unresolved corporate complexity. Q1 2026 revenue grew about 9% year over year to roughly $1.24 billion, and Q2 2026 (reported in July) brought about $1.39 billion of revenue, with adjusted EPS of $0.16 matching consensus and the GAAP net loss shrinking to about $14 million. On October 12, 2026, the company said CEO Brent Saunders would depart by mutual agreement, named Bausch Health CEO Thomas Appio as interim CEO, and said it expects to raise full-year adjusted EBITDA guidance on the back of a strong third quarter. At the same time, Bausch + Lomb remains roughly 88% owned by heavily indebted parent Bausch Health, whose long-delayed separation continues to cap the valuation. Layered on top are the residual effects of the 2025 enVista intraocular-lens recall and the company's own leverage (about $5.1 billion of debt), making this a name where the story matters as much as the numbers.

The dominant overhang is Bausch Health's roughly $20 billion of consolidated debt and the repeatedly delayed separation, which caps BLCO's valuation and creates forced-seller and solvency-test risk. Bausch + Lomb carries its own meaningful leverage (about $5.1 billion of debt against roughly $367 million of cash), so rising rates or slower EBITDA growth would pressure the balance sheet. The sudden CEO change in October 2026, with an interim chief who also runs the parent, adds execution and governance questions until a permanent leader is named. The 2025 enVista recall, tied to toxic anterior segment syndrome, was estimated to weigh on 2026 revenue by roughly $78 million and could linger as a brand and litigation risk. The company remains net-loss-making on a GAAP basis (about -$171 million TTM), RBC flagged foreign exchange turning into a modest headwind in Q3, and competition from far larger and better-capitalized rivals like Alcon, Johnson & Johnson and CooperVision is intense across every segment.

14 analysts publish price targets on BLCO, averaging $19.39 against a $16.49 price as of October 2026, or +17.6%. The published targets run from $16.00 to $24.00, a moderate spread, and the ratings split 7 buy, 7 hold, 1 sell. Over the last six months there have been 4 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full BLCO forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Bausch + Lomb Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Margin and EBITDA expansion. After years of underearning, Bausch + Lomb has been driving structural cost changes and pricing discipline. The most optimistic published target, $24.00, assumes this works close to its best case.

The case against. The dominant overhang is Bausch Health's roughly $20 billion of consolidated debt and the repeatedly delayed separation, which caps BLCO's valuation and creates forced-seller and solvency-test risk. The most pessimistic target, $16.00, is roughly what BLCO is worth if this bites instead.

Read the full bull and bear case on BLCO, including what would have to change to break either one. Walnut is not an investment adviser.

No. Bausch + Lomb Corporation (BLCO) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Bausch + Lomb Corporation's investor relations page or your broker.

• Revenue (TTM): ~$5.3B
• Revenue growth (Q2 2026, YoY): ~9%
• Q2 2026 revenue: ~$1.39B (adj. EPS $0.16 vs $0.16 est.)
• Gross / operating margin: ~61% / ~8%
• Net income (TTM): ~-$171M
• Forward P/E: ~15x
• EV/EBITDA: ~13x
• Market cap: ~$5.9B

BLCO is not yet GAAP-profitable, so investors lean on adjusted EBITDA, forward earnings and revenue growth rather than trailing multiples. At about 13 times EV/EBITDA, 15 times forward earnings and roughly 1.1 times sales, the stock trades below eye-care peers such as Alcon and The Cooper Companies, a gap that reflects the Bausch Health control discount, leverage and now a leadership transition. Q3 2026 results are due October 28, 2026, with consensus at about $1.37 billion of revenue and $0.22 of adjusted EPS, and the company has already signaled a guidance raise.

Other names that sit close to BLCO: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get BLCO exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so BLCO sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where BLCO fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

BLCO offers exposure to secular eye-care demand with improving fundamentals (TTM revenue ~$5.3 billion, losses narrowing), but the Bausch Health control overhang, leverage and a fresh leadership change keep it a higher-variance, situation-driven name. As of 2026-10-16 the stock was roughly flat for the year at about $16.47.

Whether BLCO is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is BLCO a buy or a sell?, and where the stock could go from here in the BLCO stock forecast.

For income investors, whether BLCO pays a dividend and how the payout looks is covered in does BLCO pay a dividend? And to weigh BLCO against a peer, read the full side-by-side comparisons: BLCO vs ALC and BLCO vs COO.